Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine

Patients with CLL have high rates of either severe disease or death from COVID-19 and a low response rate after COVID-19 vaccination has been reported. We conducted a single-center study with the main objective to evaluate the immunogenicity of the BNT1162b2 mRNA vaccines in 42 patients affected by...

Descripción completa

Detalles Bibliográficos
Autores principales: Galitzia, Andrea, Barabino, Luca, Murru, Roberta, Caocci, Giovanni, Greco, Marianna, Angioni, Giancarlo, Mulas, Olga, Oppi, Sara, Massidda, Stefania, Costa, Alessandro, La Nasa, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317769/
https://www.ncbi.nlm.nih.gov/pubmed/35891328
http://dx.doi.org/10.3390/vaccines10071162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317769/
https://www.ncbi.nlm.nih.gov/pubmed/35891328
http://dx.doi.org/10.3390/vaccines10071162

Ejemplares similares